To the Editor In their recent article, Jørgensen et al1 presented evidence that β-blocker use was associated with increased risk of cardiovascular events (CVE) in patients with uncomplicated hypertension undergoing noncardiac surgery. However, the authors did not consider the pitfalls that can occur when evaluating the relationship between a given treatment and adverse outcomes in an observational study.